Medicine and safety references
- Mounjaro KwikPen: UK Summary of Product Characteristics
Eli Lilly / electronic medicines compendium · Accessed 19 November 2026 - Mounjaro KwikPen: patient information leaflet
Eli Lilly / electronic medicines compendium · Accessed 19 November 2026 - MHRA authorises Mounjaro for weight management and weight loss
MHRA · Accessed 19 November 2026 - Wegovy FlexTouch: UK Summary of Product Characteristics
Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026 - Wegovy FlexTouch: patient information leaflet
Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026 - MHRA approves up to 7.2 mg semaglutide for adults with obesity
MHRA · Accessed 19 November 2026 - Wegovy tablets: UK Summary of Product Characteristics
Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026 - Wegovy tablets: patient information leaflet
Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026 - First GLP-1 tablet for weight loss approved in the UK
MHRA · Accessed 19 November 2026 - Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
Eli Lilly / electronic medicines compendium · Accessed 19 November 2026 - Foundayo: patient information leaflet
Eli Lilly / electronic medicines compendium · Accessed 19 November 2026 - UK authorises orforglipron for weight management and type 2 diabetes
MHRA · Accessed 19 November 2026 - SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine · Accessed 19 November 2026 - SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
New England Journal of Medicine · Accessed 19 November 2026 - STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · Accessed 19 November 2026 - STEP 2: Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes
The Lancet / PubMed · Accessed 19 November 2026 - STEP 4: Continued semaglutide versus placebo for weight loss maintenance
JAMA / PubMed · Accessed 19 November 2026 - STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity
The Lancet Diabetes & Endocrinology / PubMed · Accessed 19 November 2026 - OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
New England Journal of Medicine · Accessed 19 November 2026 - Wegovy oral formulation: European regulatory assessment report
European Medicines Agency · Accessed 19 November 2026 - ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
New England Journal of Medicine · Accessed 19 November 2026 - ATTAIN-2: Orforglipron for obesity in people with type 2 diabetes
The Lancet / PubMed · Accessed 19 November 2026 - TA1026: Tirzepatide for managing overweight and obesity
NICE · Accessed 19 November 2026 - TA875: Semaglutide for managing overweight and obesity
NICE · Accessed 19 November 2026 - Prescribing, reviewing and stopping tirzepatide
NICE · Accessed 19 November 2026 - Overweight and obesity management: medicines and surgery
NICE · Accessed 19 November 2026 - Weight management injections: NHS England patient information
NHS England · Accessed 19 November 2026 - Interim commissioning guidance for tirzepatide
NHS England · Accessed 19 November 2026 - Semaglutide: uses, side effects and precautions
NHS · Accessed 19 November 2026 - Overweight and obesity in adults
NHS · Accessed 19 November 2026 - GLP-1 medicines for weight loss and diabetes: what you need to know
MHRA · Accessed 19 November 2026 - GLP-1 medicines: strengthened warnings on acute pancreatitis
MHRA · Accessed 19 November 2026 - MHRA updates semaglutide guidance on very rare NAION
MHRA · Accessed 19 November 2026 - GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation
MHRA · Accessed 19 November 2026 - Dehydration: symptoms and when to get help
NHS · Accessed 19 November 2026 - Anaphylaxis: emergency symptoms and action
NHS · Accessed 19 November 2026 - Gallstones: symptoms and urgent help
NHS · Accessed 19 November 2026 - Low blood sugar: hypoglycaemia
NHS · Accessed 19 November 2026 - How to keep safe when getting medicines or treatment online
General Pharmaceutical Council and UK health organisations · Accessed 19 November 2026 - MHRA warns against buying weight loss medicines without a prescription
MHRA · Accessed 19 November 2026 - GLP-1 receptor agonists in pregnancy
UK Teratology Information Service / BUMPS · Accessed 19 November 2026 - Semaglutide tablets: NHS Scotland non-submission advice, September 2026
Scottish Medicines Consortium · Accessed 19 November 2026 - SURMOUNT-4: Continued tirzepatide for maintenance of weight reduction
JAMA · Accessed 19 November 2026 - Weight regain after semaglutide withdrawal: STEP 1 extension
Diabetes, Obesity and Metabolism · Accessed 19 November 2026 - GLP-1 treatment: nutritional considerations for prescribing clinicians
NHS Bath and North East Somerset, Swindon and Wiltshire ICB · Accessed 19 November 2026 - Patient information: GLP-1 medicines and preparing for surgery
Centre for Perioperative Care / UK multidisciplinary consensus group · Accessed 19 November 2026 - The Eatwell Guide
NHS · Accessed 19 November 2026 - Travelling with medicines and medical equipment
UK Civil Aviation Authority · Accessed 19 November 2026 - Constipation in adults
NHS · Accessed 19 November 2026 - Medicines and travel
National Travel Health Network and Centre · Accessed 19 November 2026
Price provenance
Pharmacy amounts are imported from Mango Market’s price index under permission confirmed by the site owner. These secondary-source observations are different from independently verified checkout quotes. Read the methodology.
For readers and automated tools
The canonical HTML pages contain the readable source context. The structured price snapshot preserves observation dates and unknown fees; it should not be interpreted as a live offer API. An index for automated readers points to key pages. Machine readability does not certify accuracy or guarantee inclusion in AI answers.
